Beijing, Shanghai, Boston, Oct 9, 2024 – Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today presented the pre-clinical data of SHP2 inhibitor JAB-3312 in combo with KRAS G12C inhibitor glecirasib as form of poster at the Fifth RAS Initiative Symposium 2024.

The data showed that glecirasib and JAB-3312 demonstrate potent anti-tumor effect both in vitro and in vivo, and JAB-3312 enhances the anti-tumor effect of glecirasib. Representative patients cases were also included in the poster.

The clinical data of the combination of JAB-3312 and glecirasib also verified the above preclinical conclusions. The poster released by Jacobio at ESMO 2024 showed that the confirmed objective response rate (cORR) of glecirasib and JAB-3312 as first-line treatment for non-small cell lung cancer was 70.6% (N=102), and the median progression-free survival (mPFS) remained stable at 12.2 months. Currently, a phase III registration clinical trial of JAB-3312 and glecirasib for the treatment of first-line non-small cell lung cancer harboring KRAS G12C mutation has been initiated in China.

The fifth RAS Initiative Symposium was held by Frederick National Lab which is affiliated with National Cancer Institute. For more information, please visit the official website of the conference: https://ncifrederick.cancer.gov/events/conferences/fifth-ras-initiative-...

About Glecirasib 
Glecirasib is a KRAS G12C inhibitor developed by Jacobio. A number of clinical trials of glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with cetuximab in colorectal cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China. 

About JAB-3312 
JAB-3312 is a highly selective SHP2 allosteric inhibitor with best-in-class potential. Jacobio is currently conducting clinical trials of JAB-3312 in monotherapy and combination therapies with glecirasib and other agents in China, the United States and Europe. The phase III study in combination with KRAS G12C inhibitor glecirasib has been approved by China CDE in Feb 2024. 

About Jacobio 
Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.